Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Topacal C-5 is a topical remineralizing agent formulated as a paste or gel, primarily used for the prevention and treatment of dental caries and the remineralization of early enamel lesions (white spots). It contains 5% Casein Phosphopeptide-Amorphous Calcium Phosphate (CPP-ACP), a milk-derived complex that stabilizes high concentrations of calcium and phosphate ions in an amorphous, non-crystalline state. When applied to the tooth surface, the CPP component binds to the dental biofilm and enamel, maintaining a supersaturated state of calcium and phosphate at the tooth surface. This promotes the diffusion of these minerals into the enamel subsurface, facilitating the reconstruction of hydroxyapatite crystals and reversing early demineralization. The product was developed by NSI (Nippon Shika Yakuhin) and has been evaluated in clinical trials, including those conducted by the Department of Health in Hong Kong, for its efficacy in enamel remineralization.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Topacal C-5.